glp-1 drugs shortage As Drug Ends, Why Will Patients Pay More? compounded semaglutide shortage The FDA

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

Explore the role of GLP-1 receptor agonists in neuroprotection and their impact on Alzheimer's and Parkinson's diseases.

Moreover, it remains to be shown that GIPR agonism can improve insulin secretion in type 2 diabetic patients who have been noted in previous studies to be unresponsive to GIP

Gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal pain are among the most frequently reported side effects, especially at the start of treatment

Secondary outcomes included time below and above the therapeutic range and INR variability